Is Corvus Pharmaceuticals profitable?

Corvus Pharmaceuticals is not currently profitable: it reported a net loss of $44.2M over the trailing twelve months.

What is Corvus Pharmaceuticals's earnings per share?

Corvus Pharmaceuticals's diluted EPS over the trailing twelve months is $-0.52.

Where does Corvus Pharmaceuticals's income statement data come from?

Every line is extracted from Corvus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Corvus Pharmaceuticals CRVS Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Research and development	$37.44M+64.5%	$33.72M+73.9%	$29.75M+70.9%	$26.52M+64.2%	$22.76M+42.2%
General and administrative	$10.49M+24.0%	$9.25M+13.3%	$9.11M+18.5%	$9.02M+24.5%	$8.45M+19.4%
Other operating expenses	$47.93M+53.5%	$42.97M+56.0%	$38.86M+54.9%	$35.54M+51.9%	$31.22M+35.2%
Total operating expenses	$47.93M+53.5%	$42.97M+56.0%	$38.86M+54.9%	$35.54M+51.9%	$31.22M+35.2%
Operating income	-$47.93M-53.5%	-$42.97M-56.0%	-$38.86M-54.9%	-$35.54M-51.9%	-$31.22M-35.2%
Interest income	$3.76M+85.1%	$2.51M+37.3%	$2.41M+40.8%	$2.24M+45.1%	$2.03M+35.2%
Income from equity method investments	-$2.02M+49.2%	-$1.96M+38.8%	-$3.43M-41.1%	-$3.78M-45.0%	-$3.97M-19.7%
Gain (loss) on disposal of assets	——	——	——	——	——
Income before income taxes	-$42.15M-12.6%	-$13.33M+77.5%	-$11.65M+78.6%	-$41.35M-107%	-$37.43M-73.8%
Net income	-$44.17M-6.7%	-$15.28M+75.5%	-$15.08M+73.5%	-$45.14M-99.6%	-$41.4M-66.5%
Diluted earnings per share	-$0.52+45.8%	-$0.50+47.4%	-$0.51+44.6%	-$0.99-125%	-$0.96-88.2%
Basic earnings per share	-$0.52+16.1%	-$0.16+83.2%	-$0.17+81.5%	-$0.65-47.7%	-$0.62-21.6%
Weighted-average shares, diluted	330.4M+25.8%	315.5M+33.4%	296.7M+32.8%	280.6M+36.4%	262.5M+35.7%
Weighted-average shares, basic	329.6M+27.0%	311.7M+31.8%	293.7M+31.4%	277.6M+34.9%	259.5M+34.1%
Rental Income Nonoperating	——	——	——	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$44.04M-6.4%	-$14.89M+76.2%	-$15.4M+72.6%	-$44.93M-98.8%	-$41.38M-61.0%
Gain Loss On Sale Of Property Plant Equipment	——	——	——	——	——
Net interest and investment income (loss)	$3.76M+85.1%	$2.51M+37.3%	$2.41M+40.8%	$2.24M+45.1%	$2.03M+35.2%
Unrealized gains (losses) on available-for-sale securities	-$328K—	-$17K—	——	——	——
Foreign currency translation gains (losses)	$456K+1,367%	$409K+206%	-$232K—	$174K—	-$36K—
EBIT	-$47.93M-53.5%	-$42.97M-56.0%	-$38.86M-54.9%	-$35.54M-51.9%	-$31.22M-35.2%
EBITDA	-$47.81M-53.6%	-$42.87M-56.1%	-$38.76M-55.0%	-$35.45M-52.2%	-$31.13M-35.5%
EBITDA	-$47.81M-53.6%	-$42.87M-56.1%	-$38.76M-55.0%	-$35.45M-52.2%	-$31.13M-35.5%
EBIT	-$47.93M-53.5%	-$42.97M-56.0%	-$38.86M-54.9%	-$35.54M-51.9%	-$31.22M-35.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Corvus Pharmaceuticals profitable?: Corvus Pharmaceuticals is not currently profitable: it reported a net loss of $44.2M over the trailing twelve months.
What is Corvus Pharmaceuticals's earnings per share?: Corvus Pharmaceuticals's diluted EPS over the trailing twelve months is $-0.52.
Where does Corvus Pharmaceuticals's income statement data come from?: Every line is extracted from Corvus Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.